Thanks for the great recap, some of this looks very promising! I remember reading your personal blog several years back, you (and James Watson) were both optimistic about the possibility of leveraging the Warburg effect in cancer therapies. Why didn’t much progress happen on that front? Is it that we haven’t invested the necessary resources there and instead got excited by alternative promising directions? Or did we come to learn of new information that reduced the feasibility of that strategy?
And another thought, it seems like there is some need for rapid experimentation on voluntary patients to optimize protocols (e.g. how many days to fast, whether to do oncolytic virus therapy and immune checkpoint inhibitors together etc.), and the risk-averse hyper-bureacratization around clinical trial protocols seems like a huge impediment to progress for cancer specifically.
Thanks for the great recap, some of this looks very promising! I remember reading your personal blog several years back, you (and James Watson) were both optimistic about the possibility of leveraging the Warburg effect in cancer therapies. Why didn’t much progress happen on that front? Is it that we haven’t invested the necessary resources there and instead got excited by alternative promising directions? Or did we come to learn of new information that reduced the feasibility of that strategy?
And another thought, it seems like there is some need for rapid experimentation on voluntary patients to optimize protocols (e.g. how many days to fast, whether to do oncolytic virus therapy and immune checkpoint inhibitors together etc.), and the risk-averse hyper-bureacratization around clinical trial protocols seems like a huge impediment to progress for cancer specifically.